Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tandem Diabetes Care, Inc. - Common Stock (NQ:TNDM)

20.86 -0.79 (-3.65%)
Streaming Delayed Price Updated: 2:45 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tandem Diabetes Care, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Tandem Diabetes Care to Announce First Quarter 2022 Financial Results on May 4, 2022
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Reports Mixed Q4 Earnings, Issues Better Than Expected FY22 Outlook
Tandem Diabetes Care Inc (NASDAQ: TNDM) reported Q4 sales reached $209.9 million, +25% Y/Y, beating the consensus of $199.12 million. The Company posted EPS of $0.16,... 
Via Benzinga
Expert Ratings For Tandem Diabetes Care
Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ:TNDM) stock. These analysts are typically employed by large Wall Street banks and... 
Via Benzinga
Tandem Diabetes Care: Q4 Earnings Insights
Tandem Diabetes Care (NASDAQ:TNDM) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance
From Tandem Diabetes Care, Inc.
Via Business Wire
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Tandem Diabetes Care Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces Upcoming Virtual Conference Presentations
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2021 Financial Results on February 22, 2022
From Tandem Diabetes Care, Inc.
Via Business Wire
Stock Market Rallies After Fed Meeting, But Not For Long; Adobe, Rivian, Eli Lilly In Focus: Weekly Review
Adobe and Rivian fell on guidance, while Eli Lilly jumped on its raised targets. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biofrontera (NASDAQ: 
Via Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal... 
Via Benzinga
Medtronic Hits FDA Snag For Diabetes Business — Leading A Rival To Pop
The FDA sent Medtronic a warning letter regarding its diabetes business. 
Via Investor's Business Daily
Tandem Diabetes Care Announces Expansion of Senior Leadership Team
From Tandem Diabetes Care, Inc.
Via Business Wire
2 Unstoppable Growth Stocks That Could Double Your Money in 5 Years (or Less)
These companies have a history of crushing the market. 
Via The Motley Fool
Tandem Diabetes Care to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference
From Tandem Diabetes Care, Inc.
Via Business Wire
Jim Cramer Shares His Thoughts On Innovative Industrial Properties, Nokia And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Poshmark, Inc. (NASDAQ: POSH) missed the quarter badly when others in that industry are doing quite well,... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Why Are Tandem Diabetes Shares Falling Premarket Today?
Tandem Diabetes Care Inc (NASDAQ: TNDM) reported Q3 sales of $179.6 million, +45% Y/Y, beating the consensus of $171.41 million. The Company posted EPS of $0.09, a... 
Via Benzinga
Tandem Diabetes Care, inc (TNDM) Q3 2021 Earnings Call Transcript
TNDM earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Tandem Diabetes Care: Q3 Earnings Insights
Tandem Diabetes Care (NASDAQ:TNDM) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Tandem Diabetes Care Announces Third Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces Upcoming Virtual Conference Presentations
From Tandem Diabetes Care, Inc.
Via Business Wire
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
Tandem Diabetes Care to Announce Third Quarter 2021 Financial Results on November 3, 2021
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for Tandem Diabetes Care shows improving technical performance. 
Via Investor's Business Daily
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback